Fundraising FoxThyreos
1 known investors
Find your way into Thyreos
Sign up to see every warm intro you have to Thyreos
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Thyreos team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $297.5K |
| Department of Agriculture (USDA) | Phase I | 2022 | $174.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Thyreos do?
- Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
- Who are Thyreos's investors?
- Thyreos's investors include Invest Nebraska.